ACADM and paroxysmal nocturnal hemoglobinuria: Among these 12 PNH patients who were on regular complement inhibition by eculizumab, several altered phenotypes were observed: the concentrations of acylcarnitine C6:1, the C14:1/C6 ratio (reflecting the impaired action of medium-chain acyl-CoA dehydrogenase (ACADM), and the C4/C6 ratio (reflecting the impaired action of ACADS) were significantly increased prior to receiving eculizumab.